# Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

> **NCT01970033** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 450 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Placebo
- **DRUG:** SP2086 50 mg b.i.d.
- **DRUG:** SP2086 100 mg q.d.

## Key facts

- **NCT ID:** NCT01970033
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2014-01
- **Final completion:** 2015-01
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2013-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01970033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01970033, "Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01970033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*